Akari Therapeutics (AKTX) Research & Development (2014 - 2026)
Akari Therapeutics (AKTX) posted Research & Development of $1.5 million for Q1 2026, up 34.35% sequentially from $1.1 million in Q4 2025, and up 79.46% YoY from $813000.0 in Q1 2025.
Akari Therapeutics (AKTX) Research & Development (2014 - 2026) Analysis & Trends
Akari Therapeutics (AKTX) has 9 years of Research & Development data on file, last reported at $1.5 million in Q1 2026.
- Quarterly Research & Development rose 79.46% year-over-year to $1.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $3.5 million (down 69.9% YoY) and the FY2025 annual result came in at $2.8 million, down 59.69% from the prior year.
- Research & Development climbed to $1.5 million in Q1 2026 per AKTX's latest filing, from $1.1 million in the prior quarter.
- The five-year high for Research & Development was $7.2 million in Q4 2024, with the low at -$314000.0 in Q3 2023.
- Average Research & Development over 4 years is $1.7 million, with a median of $1.5 million recorded in 2026.
- Year-over-year, Research & Development surged 188.16% in 2024 and sank 84.98% in 2025.
- Akari Therapeutics' Research & Development stood at $2.5 million in 2023, then surged by 188.16% to $7.2 million in 2024, then slumped by 84.98% to $1.1 million in 2025, then surged by 34.35% to $1.5 million in 2026.
- Business Quant data shows AKTX's Research & Development at $1.5 million in Q1 2026, $1.1 million in Q4 2025, and $249000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Genmab A | 276,399.99 Bn | 276,398.47 Bn | 831.00 Mn | -440.00 Mn |
| 2 | Akari Therapeutics | 1,217.26 Bn | 1,217.26 Bn | - | 1.46 Mn |
| 3 | BeOne Medicines | 419.38 Bn | 414.59 Bn | 1.35 Bn | 541.22 Mn |
| 4 | Vertex Pharmaceuticals | 126.54 Bn | 119.30 Bn | 2.59 Bn | 961.60 Mn |
| 5 | Pharming | 110.17 Bn | 110.12 Bn | 65.80 Mn | -25.56 Mn |
| 6 | Regeneron Pharmaceuticals | 64.97 Bn | 56.22 Bn | 3.31 Bn | 1.54 Bn |
| 7 | Argenx Se | 56.44 Bn | 56.44 Bn | 1.18 Bn | -443.00 Mn |
| 8 | Alnylam Pharmaceuticals | 40.09 Bn | 37.08 Bn | 959.66 Mn | 364.87 Mn |
| 9 | Revolution Medicines | 37.15 Bn | 37.15 Bn | - | 343.97 Mn |
| 10 | Moderna | 28.64 Bn | 23.43 Bn | -566.00 Mn | 649.00 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 1.46 Mn |
| Dec 31, 2025 | 1.09 Mn |
| Sep 30, 2025 | 249,000.00 |
| Jun 30, 2025 | 667,000.00 |
| Mar 31, 2025 | 813,000.00 |
| Dec 31, 2024 | 7.23 Mn |
| Sep 30, 2024 | 143,000.00 |
| Jun 30, 2024 | 3.31 Mn |
| Mar 31, 2024 | 2.28 Mn |
| Dec 31, 2023 | 2.51 Mn |
| Sep 30, 2023 | -314,000.00 |
| Jun 30, 2023 | 1.52 Mn |
| Mar 31, 2023 | 1.73 Mn |
| Dec 31, 2020 | 4.66 Mn |
| Sep 30, 2020 | -1.59 Mn |
| Jun 30, 2020 | 3.02 Mn |
| Mar 31, 2020 | 2.73 Mn |
| Dec 31, 2019 | 5.70 Mn |
| Sep 30, 2019 | 1.76 Mn |
| Jun 30, 2019 | 3.59 Mn |